Dasatinib Tablets

Dasatinib Tablets

Categories : Oncology

Product Packaging : 60 in HDPE

Product Composition : 20mg, 50mg, 70mg, 80mg, 100mg, 140mg

Dasatinib tablets are advanced targeted therapy medicines belonging to the class of tyrosine kinase inhibitors, widely used in the treatment of specific types of leukemia such as chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. The formulation works by inhibiting abnormal kinase activity responsible for uncontrolled cancer cell proliferation.

Genliva Wellness LLP, a pharmaceutical company located in Himatnagar, India, supplies Dasatinib tablets for export-oriented oncology markets. The company focuses on supporting pharmaceutical importers, distributors, and healthcare providers with consistent product supply, quality-focused manufacturing, and reliable delivery for cancer treatment programs.

Send Message

Dasatinib tablets are advanced targeted therapy medicines belonging to the class of tyrosine kinase inhibitors, widely used in the treatment of specific types of leukemia such as chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. The formulation works by inhibiting abnormal kinase activity responsible for uncontrolled cancer cell proliferation.

Genliva Wellness LLP, a pharmaceutical company located in Himatnagar, India, supplies Dasatinib tablets for export-oriented oncology markets. The company focuses on supporting pharmaceutical importers, distributors, and healthcare providers with consistent product supply, quality-focused manufacturing, and reliable delivery for cancer treatment programs.

  • Dasatinib tablets designed for targeted leukemia treatment protocols
  • Suitable for supply to oncology-focused distributors and hospital networks
  • Developed to support patients resistant or intolerant to prior therapies
  • Stable formulation appropriate for long-term treatment cycles
  • Available for export markets with flexible packaging and supply options
  • Part of a specialized oncology portfolio from an India-based pharma supplier
  • Treatment of chronic myeloid leukemia in chronic, accelerated, or blast phase
  • Management of Philadelphia chromosome-positive acute lymphoblastic leukemia
  • Used in patients showing resistance to other tyrosine kinase inhibitors
  • Supports targeted cancer therapy approaches in hematological malignancies
  • Oral tablet form allows easy administration without hospital-based procedures
  • Supports patient adherence in long-duration treatment plans
  • Suitable for large-scale distribution across regulated and semi-regulated markets
  • Convenient storage, transportation, and handling for export supply chains

whatsapp-app